Aerovate Therapeutics, Inc. Common Stock
AVTE Real Time Price USDRecent trades of AVTE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AVTE's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Nov. 14, 2023
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Nov. 07, 2023
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Oct. 11, 2022
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Aug. 16, 2022
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Apr. 12, 2022
-
Patent Title: Inhalable imatinib formulations, manufacture, and uses thereof Jan. 25, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of AVTE in WallStreetBets Daily Discussion
Recent insights relating to AVTE
Recent picks made for AVTE stock on CNBC
ETFs with the largest estimated holdings in AVTE
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AVTE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.